355 related articles for article (PubMed ID: 32071334)
1. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
2. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
Boudreaux SP; Duren RP; Call SG; Nguyen L; Freire PR; Narayanan P; Redell MS; Conneely OM
Leukemia; 2019 Jan; 33(1):52-63. PubMed ID: 29884904
[TBL] [Abstract][Full Text] [Related]
3. Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells.
Duren RP; Boudreaux SP; Conneely OM
PLoS One; 2016; 11(3):e0150450. PubMed ID: 26938745
[TBL] [Abstract][Full Text] [Related]
4. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
[TBL] [Abstract][Full Text] [Related]
6. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
[TBL] [Abstract][Full Text] [Related]
8. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
9. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
[TBL] [Abstract][Full Text] [Related]
10. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
11. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
12. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
13. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.
Shi J; Whyte WA; Zepeda-Mendoza CJ; Milazzo JP; Shen C; Roe JS; Minder JL; Mercan F; Wang E; Eckersley-Maslin MA; Campbell AE; Kawaoka S; Shareef S; Zhu Z; Kendall J; Muhar M; Haslinger C; Yu M; Roeder RG; Wigler MH; Blobel GA; Zuber J; Spector DL; Young RA; Vakoc CR
Genes Dev; 2013 Dec; 27(24):2648-62. PubMed ID: 24285714
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract][Full Text] [Related]
15. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
16. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
17. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
18. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
19. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia.
Boudreaux SP; Ramirez-Herrick AM; Duren RP; Conneely OM
Oncogenesis; 2012 Jul; 1(7):e19. PubMed ID: 23552735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
